


## AMENDMENTS TO THE CLAIMS

It is respectfully requested that the claims be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows. The following listing of the claims will replace all prior versions, and listings, of the claims in the application.

## LISTING OF THE CLAIMS


1-13. (Cancelled).

14. (Previously presented) A method of treating dyskinesia in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula (I):



wherein X is Oxygen or  $\text{CH}_2$ ;

$\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$  and  $\text{R}_5$  are independently Hydrogen, lower alkyl and  $\text{R}_2$  and  $\text{R}_3$  and/or  $\text{R}_4$  and  $\text{R}_5$  together may be a group of the formula (II):



wherein  $\text{R}_6$  and  $\text{R}_7$  are the same or different and are Hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring, wherein the dyskinesia is manifest as chorea or dystonia.

15. (Previously presented) The method of claim 14, wherein the compound is topiramate.

16-18. (Cancelled).

19. (Cancelled)

20-24. (Cancelled).

25-26. (Cancelled)

27. (Previously presented) The method of claim 14, wherein the dyskinesia arises as a side-effect of a therapeutic agent.

28. (New) The method of claim 14 or 27, wherein the dyskinesia is associated with dopamine replacement therapy.

29. (New) The method of claim 14 or 27, wherein the dyskinesia arises as a side-effect of the treatment of parkinsonism with a therapeutic agent.

30. (New) The method of claim 29, wherein the therapeutic agent is selected from the group consisting of ropinirole, pramipexole, cabergoline, bromocriptine, lisuride, pergolide, L-DOPA and apomorphine.

31. (New) The method of claim 27, wherein the therapeutic agent is a dopamine agonist.

32. (New) The method of claim 14, wherein the dyskinesia is levodopa-induced dyskinesia.

33. (New) The method of claim 14, wherein the compound is topiramate, and the dyskinesia is levodopa-induced dyskinesia.

34. (New) The method of claim 14, wherein the dyskinesia is associated with apomorphine treatment.

35. (New) The method of claim 14, wherein the compound is topiramate, and the dyskinesia is associated with apomorphine treatment.